Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation
Tim RH Read, Christopher K Fairley, Gerald L Murray, Jorgen S Jensen, Jennifer Danielewski, Karen Worthington, Michelle Doyle, Elisa Mokany, Litty Tan, Eric PF Chow, Suzanne M Garland, Catriona S Bradshaw
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2019
Background: Rising macrolide and quinolone resistance in Mycoplasma genitalium necessitate new treatment approaches. We evaluated outcomes of sequential antimicrobial therapy for M. genitalium guided by a macrolide-resistance assay. Methods: In mid-2016, Melbourne Sexual Health Centre switched from azithromycin to doxycycline (100 mg twice daily for 7 days) for nongonococcal urethritis, cervicitis, and proctitis. Cases were tested for M. genitalium and macrolide-resistance mutations (MRMs) by polymerase chain reaction. Directly after doxycycline, MRM-negative infections received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and MRM-positive infections received sitafloxacin (100 mg ..View full abstract
Awarded by National Health and Medical Research Council
This work was supported by early career research fellowships from the National Health and Medical Research Council (award numbers 1091536 to T. R. H. R. and 1091226 to E. P. F. C.).